This segment focuses on the research, development, and commercialization of innovative therapies for immune-mediated diseases. Acelyrin's primary focus is on izokibep, a small protein therapeutic designed to inhibit IL-17A, currently in Phase 3 clinical trials for Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, and Phase 2 trials for Axial Spondyloarthritis. Research and development activities include clinical trials, formulation development, and manufacturing process optimization. The company utilizes advanced protein engineering and antibody-based technologies. The patient impact is significant, as these therapies aim to provide new treatment options for patients with chronic and debilitating inflammatory conditions. Market positioning is centered on addressing unmet medical needs in immunology, with a competitive advantage in developing highly potent and targeted therapies. Future opportunities include expanding the clinical development of izokibep and exploring new indications. Regulatory and clinical aspects involve navigating FDA approval processes and conducting rigorous clinical trials. Partnerships with Affibody AB for izokibep development and commercialization are key to this segment's success.

This segment is dedicated to the development of lonigutamab, a humanized IgG1 monoclonal antibody against insulin-like growth factor 1 receptor (IGF-1R), for the treatment of Thyroid Eye Disease (TED). The research and development activities include Phase 1 clinical trials and the design of a Phase 3 program. The company is leveraging monoclonal antibody technology to target IGF-1R, a key driver of TED. The therapeutic area focuses on improving the quality of life for patients suffering from TED, a condition that can cause significant vision impairment and disfigurement. The market positioning involves addressing an unmet need in TED treatment, with the potential to offer a novel therapeutic option. Future opportunities include the successful completion of Phase 3 trials and potential commercialization. Regulatory and clinical aspects involve obtaining FDA approval based on clinical trial results. This segment is crucial for expanding Acelyrin's portfolio into ophthalmology and addressing a specific patient population.

This segment focuses on the preclinical development of SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, for the treatment of chronic urticaria. Research and development activities are currently in the preclinical stage, involving target validation, antibody engineering, and preclinical studies. The technology used is based on monoclonal antibody development. The therapeutic area addresses chronic urticaria, a condition characterized by recurrent hives and angioedema, significantly impacting patients' quality of life. The patient impact is aimed at providing a new treatment option for patients who do not respond to existing therapies. Market positioning involves entering the market for chronic urticaria treatments, with a focus on developing a highly specific and effective antibody. Future opportunities include advancing SLRN-517 into clinical trials and potentially commercializing the therapy. Regulatory and clinical aspects involve navigating the regulatory pathway for antibody-based therapeutics. This segment represents a strategic expansion into dermatology and addresses a significant unmet medical need.